Table 2.
Correlation of the clinic‐pathological characteristics of patients with AL amyloidosis with the expression of CT antigens
| MAGE‐C1/CT7 (n = 105) | MAGE‐C2/CT10 (n = 67) | MAGE‐A3 (n = 59) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| + | − | P | + | − | P | + | − | P | |
| PC value | 9.102 (4‐11.375) | 5.406 (3‐8.75) | 0.107 | 10.962 (5‐15) | 6.089 (4‐9) | 0.008 | 12.594 (6.5‐16.75) | 7.847 (4‐9.5) | 0.011 |
| LDH | 228.273 (179.75‐271.25) | 200.688 (174.75‐217.75) | 0.088 | 223.385 (168‐234) | 232.893 (181.5‐296.5) | 0.542 | 220.188 (152‐250.5) | 231.245 (183‐276) | 0.250 |
| β2MG | 4.294 (2.773‐5.848) | 4.798 (2.75‐8) | 0.631 | 4.204 (2.37‐5.81) | 4.942 (3.3‐8) | 0.173 | 4.077 (2.31‐6.49) | 4.674 (2.78‐6.81) | 0.398 |
| dFLC | 431.54 (58.38‐466.41) | 550.18 (67.92‐396) | 0.988 | 505.39 (84.68‐571.5) | 569.28 (69.15‐769.5) | 0.936 | 325.91 (136.49‐421.08) | 596.71 (61.11‐961.90) | 0.660 |
| NT‐pro BNP | 4112.88 (386.6‐4879.5) | 2657.05 (107‐2671) | 0.278 | 4296.0 (180.5‐4865.8) | 4056.23 (280.6‐4726.0) | 0.374 | 3552.16 (54.4‐4907.0) | 5939.8 (250.1‐3563.0) | 0.593 |
| cTnI | 0.1361 (0.0085‐0.1533) | 0.081 (0.001‐0.0325) | 0.038 | 0.085 (0.003‐0.108) | 0.164 (0.003‐0.151) | 0.695 | 0.122 (0.001‐0.193) | 0.115 (0.004‐0.084) | 0.974 |
| t(11;14) | 14.3% (10/70) | 23.1% (3/13) | 0.423 | 14.3% (5/35) | 333% (8/24) | 0.083 | 7.1% (1/14) | 25.6% (11/43) | 0.142 |
| Del(17p) | 1.4% (1/74) | 0 (0/15) | 0.651 | 0 | 0 | — | 0 | 0 | — |
| 1q21 | 25.7% (19/74) | 13.3% (2/15) | 0.305 | 29.7% (11/37) | 23.1% (6/2) | 0.558 | 66.7% (10/15) | 15.2% (7/46) | <0.001 |
Abbreviations: β2MG, β2microglobulin; cTnI, cardiac troponin; dFLC, difference between involved and uninvolved free light chain; LDH, lactate dehydrogenase; NT‐proBNP, N‐terminal fragment of the pro‐brain natriuretic peptide; PC, plasma cell.